查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1547418

全球單株抗體市場研究報告 - 2024 年至 2032 年產業分析、規模、佔有率、成長、趨勢和預測

Global Monoclonal Antibody Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032
出版日期: | 出版商: Value Market Research | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

全球單株抗體市場需求預計將從2023年的2,362.3億美元達到2032年近2,691.5億美元的市場規模，2024-2032年研究期間複合年成長率為1.46%。

單株抗體（mAb 或 moAb）是實驗室製造的蛋白質類型，可以與體內的物質結合。它們是由單一 B 細胞克隆產生的相同免疫球蛋白。單株抗體可用於治療多種疾病，可單獨使用，也可攜帶藥物、毒素或放射性物質。單株抗體有許多品種，其製備方法也不同，它們根據嵌合抗體、鼠源抗體、人源化抗體和人源抗體的製備方式來命名。單株抗體可辨識單一抗原上的獨特抗原決定位或結合位點。它們在免疫系統中的作用類似人類抗體。

市場動態

單株抗體（mAb 或 moAb）已成為生物化學、分子生物學和醫學的重要工具。慢性病和癌症發病率的上升、監管部門批准的增加、療法的推出以及研發的不斷成長主要推動了全球單株抗體市場。慢性病和癌症是全世界死亡的主要原因。根據世界衛生組織估計，全球約三分之二的死亡是由慢性病造成的。 2020年，癌症導致近千萬人死亡。隨著 COVID-19 大流行的興起，單株抗體引起了人們的關注。它們已經取得了進展，可以得到更廣泛的使用。單株抗體為製藥業和治療 COVID-19 大流行提供了許多好處，包括生產時間短、成本低、高度穩定且耐受 pH 或緩衝液變化、高親和力以及對微小抗原變化的耐受性。單株抗體被認為是治療 COVID-19 患者的一種有前途的方法。正在進行強力的研究，以利用它來治療 COVID-19。然而，與單株抗體相關的較高成本、嚴格的監管措施、對單株抗體的認知較低以及缺乏研究可能會阻礙市場成長。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具也對全球單株抗體市場的各個細分市場進行了包容性評估。單株抗體產業的成長和趨勢為本研究提供了整體方法。

市場區隔

單株抗體市場報告的這一部分提供了國家和區域層面細分市場的詳細資料，從而幫助策略師確定相應產品或服務的目標人群以及即將到來的機會。

按來源

  • 鼠類
  • 嵌合體
  • 人性化
  • 人類

按產量

  • 體內
  • 體外

按申請

  • 腫瘤學
  • 自體免疫疾病
  • 傳染病
  • 神經系統疾病
  • 其他

按最終用途

  • 醫院
  • 專科中心
  • 其他

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲單株抗體市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。單株抗體市場的主要參與者包括諾華公司、輝瑞公司、葛蘭素史克公司、安進公司、默克公司、第一三共有限公司、雅培實驗室、阿斯特捷利康公司、禮來公司、強生服務公司Inc.、拜耳股份公司、Bristol Myers Squibb、F. Hoffman-La Roche Ltd.、Viatris Inc.、Biogen Inc.、Thermo Fisher Scientific Inc.、Novo Nordisk A/S、Sanofi SA、Merck KGaA。本節包含競爭格局的整體視圖，包括各種策略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

目錄

第1章：前言

  • 報告說明
    • 客觀的
    • 目標受眾
    • 獨特的銷售主張 (USP) 和產品
  • 研究範圍
  • 研究方法
    • 市場研究過程
    • 市場研究方法論

第 2 章：執行摘要

  • 市場亮點
  • 全球市場概況

第 3 章：單株抗體 - 產業分析

  • 簡介 - 市場動態
  • 市場促進因素
  • 市場限制
  • 機會
  • 產業動態
  • 波特五力分析
  • 市場吸引力分析
    • 按來源分類的市場吸引力分析
    • 按產量分析市場吸引力
    • 市場吸引力分析：依應用分類
    • 按最終用途分類的市場吸引力分析
    • 市場吸引力分析：按地區

第 4 章：價值鏈分析

  • 價值鏈分析
  • 原料分析
    • 原料清單
    • 原料廠商清單
    • 主要原物料價格走勢
  • 潛在買家名單
  • 行銷管道
    • 直效行銷
    • 間接行銷
    • 行銷通路發展趨勢

第 5 章：全球單株抗體市場分析：依來源分類

  • 按來源概述
  • 按來源分類的歷史和預測資料分析
  • 鼠類
  • 嵌合體
  • 人性化
  • 人類

第 6 章：全球單株抗體市場分析：依產量分類

  • 按生產概覽
  • 按生產進行的歷史和預測數據分析
  • 體內
  • 體外

第 7 章：全球單株抗體市場分析：依應用分類

  • 概述：按應用
  • 歷史與預測資料分析：按應用分類
  • 腫瘤學
  • 自體免疫疾病
  • 傳染病
  • 神經系統疾病
  • 其他

第 8 章：全球單株抗體市場分析：依最終用途分類

  • 按最終用途分類的概述
  • 按最終用途分類的歷史和預測資料分析
  • 醫院
  • 專科中心
  • 其他

第 9 章：全球單株抗體市場分析：依地理位置

  • 區域展望
  • 介紹
  • 北美銷售分析
    • 概覽、歷史與預測資料銷售分析
    • 北美按細分市場銷售分析
    • 北美按國家銷售分析
    • 美國銷售分析
    • 加拿大銷售分析
    • 墨西哥銷售分析
  • 歐洲銷售分析
    • 概覽、歷史與預測資料銷售分析
    • 歐洲按細分市場銷售分析
    • 歐洲按國家銷售分析
    • 英國銷售分析
    • 法國銷售分析
    • 德國銷售分析
    • 義大利銷售分析
    • 俄羅斯銷售分析
    • 歐洲其他地區銷售分析
  • 亞太地區銷售分析
    • 概覽、歷史與預測資料銷售分析
    • 亞太地區按細分市場銷售分析
    • 亞太地區按國家銷售分析
    • 中國銷售分析
    • 印度銷售分析
    • 日本銷售分析
    • 韓國銷售分析
    • 澳洲銷售分析
    • 東南亞銷售分析
    • 亞太地區其他地區銷售分析
  • 拉丁美洲銷售分析
    • 概覽、歷史與預測資料銷售分析
    • 拉丁美洲按細分市場銷售分析
    • 拉丁美洲按國家銷售分析
    • 巴西銷售分析
    • 阿根廷銷售分析
    • 秘魯銷售分析
    • 智利銷售分析
    • 拉丁美洲其他地區銷售分析
  • 中東和非洲銷售分析
    • 概覽、歷史與預測資料銷售分析
    • 中東和非洲按細分市場銷售分析
    • 中東和非洲按國家銷售分析
    • 沙烏地阿拉伯銷售分析
    • 阿拉伯聯合大公國銷售分析
    • 以色列銷售分析
    • 南非銷售分析
    • 中東其他地區和非洲銷售分析

第 10 章：單株抗體公司的競爭格局

  • 單株抗體市場競爭
  • 夥伴關係/協作/協議
  • 併購
  • 新產品發布
  • 其他發展

第 11 章：公司簡介

  • 頂級公司市佔率分析
  • 市場集中度
  • Novartis AG
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Pfizer Inc
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • GlaxoSmithKline Plc
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Amgen Inc.
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Merck & Co. Inc.
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Daiichi Sankyo Company
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Limited
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Abbott Laboratories
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • AstraZeneca Plc
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Eli Lilly And Company
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Johnson & Johnson Services Inc.
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Bayer AG
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Bristol Myers Squibb
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • F. Hoffman-La Roche Ltd.
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Viatris Inc.
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Biogen Inc.
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Thermo Fisher Scientific Inc.
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Novo Nordisk A/S
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Sanofi SA
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態
  • Merck KGaA
    • 公司概況
    • 公司收入
    • 產品
    • 最新動態

註 - 在公司概況中，財務詳細資訊和最新發展視情況而定，或對私人公司而言可能不包括在內

Product Code: VMR11215463

The global demand for Monoclonal Antibody Market is presumed to reach the market size of nearly USD 269.15 Billion by 2032 from USD 236.23 Billion in 2023 with a CAGR of 1.46% under the study period 2024-2032.

Monoclonal antibodies (mAb or moAb) are a protein type made in the laboratory that can bind to substances in the body. They are identical immunoglobulins generated from a single B-cell clone. Monoclonal antibodies are employed to treat many diseases and can be used alone or carry drugs, toxins, or radioactive substances. There are many varieties of monoclonal antibodies and different ways of making them, and they are named based on how they are made of chimeric, murine, humanized, and human. Monoclonal antibodies recognize unique epitopes, or binding sites, on a single antigen. They act like human antibodies in the immune system.

MARKET DYNAMICS

Monoclonal antibodies (mAb or moAb) have become an important tool in biochemistry, molecular biology, and medicine. Rising incidence of chronic diseases and cancer, increasing regulatory approvals, the launch of therapies, and growing R&D primarily drive the global monoclonal antibody market. Chronic diseases and cancer are the leading cause of death worldwide. According to the World Health Organization estimates, chronic diseases are responsible for around two-thirds of all deaths worldwide. In 2020, cancer caused the death of nearly 10 million people. Monoclonal antibodies have gained attention with the rise of the COVID-19 pandemic. They have progressed to allow more widespread use. Monoclonal antibodies offer many benefits to the pharmaceutical industry and treat the COVID-19 pandemic, including short production time, low cost, highly stable and tolerant of pH or buffer changes, high affinity, and tolerance of minor antigen changes. Monoclonal antibodies are identified as a promising approach for treating COVID-19 patients. Robust research is being carried out to use it to treat COVID-19. However, higher costs associated with a monoclonal antibody, strict regulatory measures, low awareness about monoclonal antibody, and lack of research is likely to hamper the market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Monoclonal Antibody. The growth and trends of Monoclonal Antibody industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Monoclonal Antibody market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Source

  • Murine
  • Chimeric
  • Humanized
  • Human

By Production

  • In Vivo
  • In Vitro

By Application

  • Oncology
  • Autoimmune Diseases
  • Infectious Diseases
  • Neurological Diseases
  • Others

By End-use

  • Hospitals
  • Specialty Centers
  • Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Monoclonal Antibody market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Monoclonal Antibody market include Novartis AG, Pfizer Inc, GlaxoSmithKline Plc, Amgen Inc., Merck & Co. Inc., Daiichi Sankyo Company, Limited, Abbott Laboratories, AstraZeneca Plc, Eli Lilly And Company, Johnson & Johnson Services Inc., Bayer AG, Bristol Myers Squibb, F. Hoffman-La Roche Ltd., Viatris Inc., Biogen Inc., Thermo Fisher Scientific Inc., Novo Nordisk A/S, Sanofi S.A., Merck KGaA. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. MONOCLONAL ANTIBODY - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Source
    • 3.7.2 Market Attractiveness Analysis By Production
    • 3.7.3 Market Attractiveness Analysis By Application
    • 3.7.4 Market Attractiveness Analysis By End-use
    • 3.7.5 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL MONOCLONAL ANTIBODY MARKET ANALYSIS BY SOURCE

  • 5.1. Overview By Source
  • 5.2. Historical and Forecast Data Analysis By Source
  • 5.3. Murine Historic and Forecast Sales By Regions
  • 5.4. Chimeric Historic and Forecast Sales By Regions
  • 5.5. Humanized Historic and Forecast Sales By Regions
  • 5.6. Human Historic and Forecast Sales By Regions

6. GLOBAL MONOCLONAL ANTIBODY MARKET ANALYSIS BY PRODUCTION

  • 6.1. Overview By Production
  • 6.2. Historical and Forecast Data Analysis By Production
  • 6.3. In Vivo Historic and Forecast Sales By Regions
  • 6.4. In Vitro Historic and Forecast Sales By Regions

7. GLOBAL MONOCLONAL ANTIBODY MARKET ANALYSIS BY APPLICATION

  • 7.1. Overview By Application
  • 7.2. Historical and Forecast Data Analysis By Application
  • 7.3. Oncology Historic and Forecast Sales By Regions
  • 7.4. Autoimmune Diseases Historic and Forecast Sales By Regions
  • 7.5. Infectious Diseases Historic and Forecast Sales By Regions
  • 7.6. Neurological Diseases Historic and Forecast Sales By Regions
  • 7.7. Others Historic and Forecast Sales By Regions

8. GLOBAL MONOCLONAL ANTIBODY MARKET ANALYSIS BY END-USE

  • 8.1. Overview By End-use
  • 8.2. Historical and Forecast Data Analysis By End-use
  • 8.3. Hospitals Historic and Forecast Sales By Regions
  • 8.4. Specialty Centers Historic and Forecast Sales By Regions
  • 8.5. Others Historic and Forecast Sales By Regions

9. GLOBAL MONOCLONAL ANTIBODY MARKET ANALYSIS BY GEOGRAPHY

  • 9.1. Regional Outlook
  • 9.2. Introduction
  • 9.3. North America Sales Analysis
    • 9.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.3.2 North America By Segment Sales Analysis
    • 9.3.3 North America By Country Sales Analysis
    • 9.3.4 United States Sales Analysis
    • 9.3.5 Canada Sales Analysis
    • 9.3.6 Mexico Sales Analysis
  • 9.4. Europe Sales Analysis
    • 9.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.4.2 Europe By Segment Sales Analysis
    • 9.4.3 Europe By Country Sales Analysis
    • 9.4.4 United Kingdom Sales Analysis
    • 9.4.5 France Sales Analysis
    • 9.4.6 Germany Sales Analysis
    • 9.4.7 Italy Sales Analysis
    • 9.4.8 Russia Sales Analysis
    • 9.4.9 Rest Of Europe Sales Analysis
  • 9.5. Asia Pacific Sales Analysis
    • 9.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.5.2 Asia Pacific By Segment Sales Analysis
    • 9.5.3 Asia Pacific By Country Sales Analysis
    • 9.5.4 China Sales Analysis
    • 9.5.5 India Sales Analysis
    • 9.5.6 Japan Sales Analysis
    • 9.5.7 South Korea Sales Analysis
    • 9.5.8 Australia Sales Analysis
    • 9.5.9 South East Asia Sales Analysis
    • 9.5.10 Rest Of Asia Pacific Sales Analysis
  • 9.6. Latin America Sales Analysis
    • 9.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.6.2 Latin America By Segment Sales Analysis
    • 9.6.3 Latin America By Country Sales Analysis
    • 9.6.4 Brazil Sales Analysis
    • 9.6.5 Argentina Sales Analysis
    • 9.6.6 Peru Sales Analysis
    • 9.6.7 Chile Sales Analysis
    • 9.6.8 Rest of Latin America Sales Analysis
  • 9.7. Middle East & Africa Sales Analysis
    • 9.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 9.7.2 Middle East & Africa By Segment Sales Analysis
    • 9.7.3 Middle East & Africa By Country Sales Analysis
    • 9.7.4 Saudi Arabia Sales Analysis
    • 9.7.5 UAE Sales Analysis
    • 9.7.6 Israel Sales Analysis
    • 9.7.7 South Africa Sales Analysis
    • 9.7.8 Rest Of Middle East And Africa Sales Analysis

10. COMPETITIVE LANDSCAPE OF THE MONOCLONAL ANTIBODY COMPANIES

  • 10.1. Monoclonal Antibody Market Competition
  • 10.2. Partnership/Collaboration/Agreement
  • 10.3. Merger And Acquisitions
  • 10.4. New Product Launch
  • 10.5. Other Developments

11. COMPANY PROFILES OF MONOCLONAL ANTIBODY INDUSTRY

  • 11.1. Top Companies Market Share Analysis
  • 11.2. Market Concentration Rate
  • 11.3. Novartis AG
    • 11.3.1 Company Overview
    • 11.3.2 Company Revenue
    • 11.3.3 Products
    • 11.3.4 Recent Developments
  • 11.4. Pfizer Inc
    • 11.4.1 Company Overview
    • 11.4.2 Company Revenue
    • 11.4.3 Products
    • 11.4.4 Recent Developments
  • 11.5. GlaxoSmithKline Plc
    • 11.5.1 Company Overview
    • 11.5.2 Company Revenue
    • 11.5.3 Products
    • 11.5.4 Recent Developments
  • 11.6. Amgen Inc.
    • 11.6.1 Company Overview
    • 11.6.2 Company Revenue
    • 11.6.3 Products
    • 11.6.4 Recent Developments
  • 11.7. Merck & Co. Inc.
    • 11.7.1 Company Overview
    • 11.7.2 Company Revenue
    • 11.7.3 Products
    • 11.7.4 Recent Developments
  • 11.8. Daiichi Sankyo Company
    • 11.8.1 Company Overview
    • 11.8.2 Company Revenue
    • 11.8.3 Products
    • 11.8.4 Recent Developments
  • 11.9. Limited
    • 11.9.1 Company Overview
    • 11.9.2 Company Revenue
    • 11.9.3 Products
    • 11.9.4 Recent Developments
  • 11.10. Abbott Laboratories
    • 11.10.1 Company Overview
    • 11.10.2 Company Revenue
    • 11.10.3 Products
    • 11.10.4 Recent Developments
  • 11.11. AstraZeneca Plc
    • 11.11.1 Company Overview
    • 11.11.2 Company Revenue
    • 11.11.3 Products
    • 11.11.4 Recent Developments
  • 11.12. Eli Lilly And Company
    • 11.12.1 Company Overview
    • 11.12.2 Company Revenue
    • 11.12.3 Products
    • 11.12.4 Recent Developments
  • 11.13. Johnson & Johnson Services Inc.
    • 11.13.1 Company Overview
    • 11.13.2 Company Revenue
    • 11.13.3 Products
    • 11.13.4 Recent Developments
  • 11.14. Bayer AG
    • 11.14.1 Company Overview
    • 11.14.2 Company Revenue
    • 11.14.3 Products
    • 11.14.4 Recent Developments
  • 11.15. Bristol Myers Squibb
    • 11.15.1 Company Overview
    • 11.15.2 Company Revenue
    • 11.15.3 Products
    • 11.15.4 Recent Developments
  • 11.16. F. Hoffman-La Roche Ltd.
    • 11.16.1 Company Overview
    • 11.16.2 Company Revenue
    • 11.16.3 Products
    • 11.16.4 Recent Developments
  • 11.17. Viatris Inc.
    • 11.17.1 Company Overview
    • 11.17.2 Company Revenue
    • 11.17.3 Products
    • 11.17.4 Recent Developments
  • 11.18. Biogen Inc.
    • 11.18.1 Company Overview
    • 11.18.2 Company Revenue
    • 11.18.3 Products
    • 11.18.4 Recent Developments
  • 11.19. Thermo Fisher Scientific Inc.
    • 11.19.1 Company Overview
    • 11.19.2 Company Revenue
    • 11.19.3 Products
    • 11.19.4 Recent Developments
  • 11.20. Novo Nordisk A/S
    • 11.20.1 Company Overview
    • 11.20.2 Company Revenue
    • 11.20.3 Products
    • 11.20.4 Recent Developments
  • 11.21. Sanofi S.A.
    • 11.21.1 Company Overview
    • 11.21.2 Company Revenue
    • 11.21.3 Products
    • 11.21.4 Recent Developments
  • 11.22. Merck KGaA
    • 11.22.1 Company Overview
    • 11.22.2 Company Revenue
    • 11.22.3 Products
    • 11.22.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies

LIST OF TABLES

  • Market Snapshot
  • Drivers: Impact Analysis
  • Restraints: Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • Analysis By Source (USD MN)
  • Murine Market Sales By Geography (USD MN)
  • Chimeric Market Sales By Geography (USD MN)
  • Humanized Market Sales By Geography (USD MN)
  • Human Market Sales By Geography (USD MN)
  • Analysis By Production (USD MN)
  • In Vivo Market Sales By Geography (USD MN)
  • In Vitro Market Sales By Geography (USD MN)
  • Analysis By Application (USD MN)
  • Oncology Market Sales By Geography (USD MN)
  • Autoimmune Diseases Market Sales By Geography (USD MN)
  • Infectious Diseases Market Sales By Geography (USD MN)
  • Neurological Diseases Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Analysis By End-use (USD MN)
  • Hospitals Market Sales By Geography (USD MN)
  • Specialty Centers Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Monoclonal Antibody Market Sales By Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United States Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate By Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Monoclonal Antibody Report
  • Market Research Process
  • Market Research Methodology
  • Global Monoclonal Antibody Market Size, By Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis By Source
  • Market Attractiveness Analysis By Production
  • Market Attractiveness Analysis By Application
  • Market Attractiveness Analysis By End-use
  • Market Attractiveness Analysis By Region
  • Value Chain Analysis
  • Global Market Analysis By Source (USD MN)
  • Murine Market Sales By Geography (USD MN)
  • Chimeric Market Sales By Geography (USD MN)
  • Humanized Market Sales By Geography (USD MN)
  • Human Market Sales By Geography (USD MN)
  • Global Market Analysis By Production (USD MN)
  • In Vivo Market Sales By Geography (USD MN)
  • In Vitro Market Sales By Geography (USD MN)
  • Global Market Analysis By Application (USD MN)
  • Oncology Market Sales By Geography (USD MN)
  • Autoimmune Diseases Market Sales By Geography (USD MN)
  • Infectious Diseases Market Sales By Geography (USD MN)
  • Neurological Diseases Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Analysis By End-use (USD MN)
  • Hospitals Market Sales By Geography (USD MN)
  • Specialty Centers Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.